CompletedPhase 4NCT03939520
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospices Civils de Lyon
- Principal Investigator
- Vincent COTTIN, PrHospices Civils de Lyon
- Intervention
- pirfenidone and nintedanib(drug)
- Enrollment
- 279 enrolled
- Eligibility
- 50 years · All sexes
- Timeline
- 2020 – 2026
Study locations (22)
- CHU d'Angers, Angers, France
- Centre Hospitalier de la côte Basque, Bayonne, France
- CHRU de Besançon - Hôpital Jean Minjoz, Besançon, France
- AP - HP - Hôpital Avicenne, Bobigny, France
- CHRU Hôpital Cavale Blanche, Brest, France
- Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France
- CHU de Caen - Hôpital de la Côte de Nacre, Caen, France
- CHU Dijon Bourgogne - Hôpital François Mitterrand, Dijon, France
- CHRU de Lille - Hôpital Albert Calmette, Lille, France
- CHU de Marseille - Hôpital Nord, Marseille, France
- CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, France
- CHU - Hôpital G.R. Laennec, Nantes, France
- CHU de Nice, Hôpital Pasteur, Nice, France
- APHP - Hôpital Xavier Bichat-Claude Bernard, Paris, France
- Groupe Hospitalier Paris Saint Joseph, Paris, France
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03939520 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics